Equity Overview
Price & Market Data
Price: $1.66
Daily Change: +$0.14 / 8.43%
Daily Range: $1.47 - $1.73
Market Cap: $7,267,214
Daily Volume: 452,438
Performance Metrics
1 Week: 12.93%
1 Month: -38.06%
3 Months: 40.68%
6 Months: -43.15%
1 Year: -89.98%
YTD: -81.24%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.